FDA approves ZANVASTRO for Alexander disease, expanding access
FDA approved ZANVASTRO as the first disease-modifying therapy for Alexander disease, with a broad label for children and adults. Approval was based on clinical data showing motor function benefit and favorable safety.
FDA approved ZANVASTRO as the first disease-modifying therapy for Alexander disease, giving it a broad label for children and adults. The decision was supported by clinical data showing a significant benefit in motor function and a favorable safety profile. Launch efforts are focused on rapid patient access and payer coverage.